ALLMedicine™ Triple-negative Breast Cancer Center
Research & Reviews 5,977 results
https://doi.org/10.1038/s41388-021-01691-y 10.1016/S1470-2045(14)70364-X 10.1083/jcb.201903066 10.1242/jcs.072165 10.1016/j.canlet.2016.12.001 10.1016/j.stem.2014.02.002 10.1016/j.cell.2016.11.037 10.1016/j.cytogfr.2012.06.004 10.1038/s41571-018-0113-0 10.1038/onc.2009.61 10.1038/s41388-019-0756-z 10.1093/carcin/bgq180 10.1038/nature09161 10.18632/oncotarget.10360 10.1073/pnas.0506580102 10.1093/emboj/18.3.616 10.1158/1535-7163.MCT-15-0758 10.1016/0896-6273(94)90327-1 10.1074/jbc.M117.788729 10.1101/gad.277681.116 10.1006/bbrc.2001.4896 10.7150/jca.16901 10.1002/1878-0261.12098 10.1093/nar/gkw983 10.1038/nature22794 10.1158/2159-8290.CD-12-0095 10.1186/1471-2407-14-970 10.1371/journal.pone.0182666 10.1016/j.neo.2017.05.002 10.1093/nar/gkz430 10.1016/j.molcel.2015.10.031 10.1016/j.cellsig.2010.07.014 10.1016/j.ajpath.2017.09.008 10.1038/s41467-017-01573-6 10.1242/jcs.129387 10.1038/onc.2016.195 10.1002/bit.25572
Oncogene Wu R, Li K et. al.
Feb 25th, 2021 - Cellular heterogeneity and the lack of metastatic biomarkers limit the diagnosis of and development of therapies for metastatic triple-negative breast cancer (TNBC). Thus, development of new clinically relevant markers is urgently needed. By using...
https://doi.org/10.21873/cgp.20249
Cancer Genomics & Proteomics; Ntzifa A, Strati A et. al.
Feb 20th, 2021 - Effective targeted therapies for triple-negative breast cancer (TNBC) are limited. In a subset of TNBC, androgen receptor (AR) plays an important role, while the human proviral integration site for Moloney murine leukemia virus-1 (PIM1) overexpres...
https://doi.org/10.1016/j.canlet.2021.02.009
Cancer Letters; Huang M, Zhou Y et. al.
Feb 19th, 2021 - Increasing evidence suggested that a number of ubiquitin enzymes, including ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, E3 ubiquitin ligases and deubiquitination enzymes contribute to therapeutic resistance in triple-negative brea...
https://doi.org/10.1007/s10549-021-06127-5 10.1056/NEJMra1001389 10.1177/548.6505 10.1200/JCO.2011.38.2010 10.3390/cancers12092392 10.3322/caac.21565 10.1158/1078-0432.CCR-14-2258 10.1038/bjc.2011.177 10.1158/1078-0432.CCR-14-0816 10.1007/s40265-015-0379-9 10.1056/NEJMoa1609709 10.3390/cells8040321 10.1186/bcr2419 10.1186/bcr2142 10.1007/s10549-018-05104-9 10.1038/s41598-019-43429-7 10.1158/1078-0432.CCR-17-0369 10.1158/0008-5472.CAN-17-2210 10.1038/ncomms13923 10.1038/s41598-019-49484-4 10.1007/s00018-019-03281-4 10.3389/fgene.2014.00098 10.3390/cancers11050684 10.1172/JCI15593 10.1101/cshperspect.a004754 10.1007/s10549-007-9756-8 10.1158/0008-5472.CAN-15-0728 10.3390/ijms19072043 10.1158/0008-5472.CAN-07-2489 10.3390/cells9030668 10.1074/jbc.M702854200 10.1177/1010428317698338 10.20517/cdr.2019.100 10.1016/j.cmet.2015.12.006 10.1038/oncsis.2015.49 10.1016/j.canlet.2017.05.002 10.1016/j.cmet.2018.04.018 10.1016/j.cmet.2015.12.004 10.1016/j.celrep.2019.11.008 10.1007/s10549-005-6654-9 10.7150/jca.18743 10.1016/j.bbrc.2013.08.043 10.3390/genes11040467 10.1007/s12282-020-01150-8
Breast Cancer Research and Treatment; Lanceta L, Lypova N et. al.
Feb 18th, 2021 - The management of triple-negative breast cancer (TNBC) remains a significant clinical challenge due to the lack of effective targeted therapies. Inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6) are emerging as promising therapeutic agen...
https://doi.org/10.1001/jamaoncol.2020.7310
JAMA Oncology; Filho OM, Stover DG et. al.
Feb 18th, 2021 - Adding carboplatin to standard neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) likely benefits a subset of patients; however, determinants of benefit are poorly understood. To define the association of molecular subtype, tum...
Guidelines 37 results
https://www.medpagetoday.com/meetingcoverage/asco/86804
May 31st, 2020
https://www.mdedge.com/hematology-oncology/article/223054/breast-cancer/expanding-role-parp-inhibitors-breast-cancer
May 30th, 2020 - For patients with BRCA-like triple-negative breast cancer (TNBC), adding veliparib to cisplatin chemotherapy may extend survival, based on results from the phase 3 SWOG S1416 trial.
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{3c339a48-87d5-48c1-ad53-432291e3e553}/metronomic-capecitabine-maintenance-extends-dfs-in-triple-negative-breast-cancer
May 29th, 2020 - A year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer, according to study results presented at ASCO20 Virtual Scientific Program.
https://www.mdedge.com/hematology-oncology/article/223037/breast-cancer/ppi-added-chemo-improves-breast-tumor-response-rate
May 29th, 2020 - The proton pump inhibitor (PPI) omeprazole may be a useful addition to treatment for triple-negative breast cancer, as it boosted the expected rate of tumor disappearance among women with early-stage disease, according to the results of a phase 2 ...
https://www.mdedge.com/hematology-oncology/article/223038/breast-cancer/capecitabine-maintenance-improved-dfs-not-os-tnbc
May 29th, 2020 - For patients with triple-negative breast cancer (TNBC), 1 year of capecitabine treatment after standard therapy may lead to significantly better disease-free survival (DFS), but not overall survival (OS), according to results of a phase 3 trial.
Drugs 1 results see all →
Clinicaltrials.gov 6,621 results
https://doi.org/10.1038/s41388-021-01691-y 10.1016/S1470-2045(14)70364-X 10.1083/jcb.201903066 10.1242/jcs.072165 10.1016/j.canlet.2016.12.001 10.1016/j.stem.2014.02.002 10.1016/j.cell.2016.11.037 10.1016/j.cytogfr.2012.06.004 10.1038/s41571-018-0113-0 10.1038/onc.2009.61 10.1038/s41388-019-0756-z 10.1093/carcin/bgq180 10.1038/nature09161 10.18632/oncotarget.10360 10.1073/pnas.0506580102 10.1093/emboj/18.3.616 10.1158/1535-7163.MCT-15-0758 10.1016/0896-6273(94)90327-1 10.1074/jbc.M117.788729 10.1101/gad.277681.116 10.1006/bbrc.2001.4896 10.7150/jca.16901 10.1002/1878-0261.12098 10.1093/nar/gkw983 10.1038/nature22794 10.1158/2159-8290.CD-12-0095 10.1186/1471-2407-14-970 10.1371/journal.pone.0182666 10.1016/j.neo.2017.05.002 10.1093/nar/gkz430 10.1016/j.molcel.2015.10.031 10.1016/j.cellsig.2010.07.014 10.1016/j.ajpath.2017.09.008 10.1038/s41467-017-01573-6 10.1242/jcs.129387 10.1038/onc.2016.195 10.1002/bit.25572
Oncogene Wu R, Li K et. al.
Feb 25th, 2021 - Cellular heterogeneity and the lack of metastatic biomarkers limit the diagnosis of and development of therapies for metastatic triple-negative breast cancer (TNBC). Thus, development of new clinically relevant markers is urgently needed. By using...
https://ascopost.com/issues/february-25-2021/i-let-science-not-emotion-dictate-my-treatment/
Feb 24th, 2021 - When I was diagnosed with metastatic triple-negative breast cancer, a clinical trial offered me a 4% chance at remission. I took it. I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy ...
https://doi.org/10.21873/cgp.20249
Cancer Genomics & Proteomics; Ntzifa A, Strati A et. al.
Feb 20th, 2021 - Effective targeted therapies for triple-negative breast cancer (TNBC) are limited. In a subset of TNBC, androgen receptor (AR) plays an important role, while the human proviral integration site for Moloney murine leukemia virus-1 (PIM1) overexpres...
https://doi.org/10.1016/j.canlet.2021.02.009
Cancer Letters; Huang M, Zhou Y et. al.
Feb 19th, 2021 - Increasing evidence suggested that a number of ubiquitin enzymes, including ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, E3 ubiquitin ligases and deubiquitination enzymes contribute to therapeutic resistance in triple-negative brea...
https://doi.org/10.1007/s10549-021-06127-5 10.1056/NEJMra1001389 10.1177/548.6505 10.1200/JCO.2011.38.2010 10.3390/cancers12092392 10.3322/caac.21565 10.1158/1078-0432.CCR-14-2258 10.1038/bjc.2011.177 10.1158/1078-0432.CCR-14-0816 10.1007/s40265-015-0379-9 10.1056/NEJMoa1609709 10.3390/cells8040321 10.1186/bcr2419 10.1186/bcr2142 10.1007/s10549-018-05104-9 10.1038/s41598-019-43429-7 10.1158/1078-0432.CCR-17-0369 10.1158/0008-5472.CAN-17-2210 10.1038/ncomms13923 10.1038/s41598-019-49484-4 10.1007/s00018-019-03281-4 10.3389/fgene.2014.00098 10.3390/cancers11050684 10.1172/JCI15593 10.1101/cshperspect.a004754 10.1007/s10549-007-9756-8 10.1158/0008-5472.CAN-15-0728 10.3390/ijms19072043 10.1158/0008-5472.CAN-07-2489 10.3390/cells9030668 10.1074/jbc.M702854200 10.1177/1010428317698338 10.20517/cdr.2019.100 10.1016/j.cmet.2015.12.006 10.1038/oncsis.2015.49 10.1016/j.canlet.2017.05.002 10.1016/j.cmet.2018.04.018 10.1016/j.cmet.2015.12.004 10.1016/j.celrep.2019.11.008 10.1007/s10549-005-6654-9 10.7150/jca.18743 10.1016/j.bbrc.2013.08.043 10.3390/genes11040467 10.1007/s12282-020-01150-8
Breast Cancer Research and Treatment; Lanceta L, Lypova N et. al.
Feb 18th, 2021 - The management of triple-negative breast cancer (TNBC) remains a significant clinical challenge due to the lack of effective targeted therapies. Inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6) are emerging as promising therapeutic agen...
News 427 results
https://www.medscape.com/viewarticle/945174
Feb 2nd, 2021 - Researchers say women with type 2 diabetes treated with metformin had a reduced rate of the most common type of breast cancer, estrogen receptor (ER)-positive tumors, during a median follow-up of nearly 9 years in a prospective study of more than ...
https://www.medscape.com/viewarticle/942747
Dec 15th, 2020 - Adding the oral AKT inhibitor ipatasertib to paclitaxel does not improve progression-free survival (PFS) for women with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), suggests the phase ...
https://www.medscape.com/viewarticle/942693
Dec 14th, 2020 - Adding pembrolizumab (Keytruda) to chemotherapy substantially increases progression-free survival (PFS) in treatment-naive advanced or metastatic triple-negative breast cancer (TNBC) regardless of chemotherapy type, suggests an analysis of the cli...
https://www.medscape.com/viewarticle/942562
Dec 13th, 2020 - The antibody–drug conjugate sacituzumab govitecan (SG) (Trodelvy) appears to be effective across biomarker subgroups for women with metastatic triple-negative breast cancer (mTNBC) that has progressed after multiple lines of therapy, a biomarker e...
https://www.medscape.com/viewarticle/942620
Dec 13th, 2020 - Adding the immune checkpoint inhibitor atezolizumab to first-line therapy for early triple-negative breast cancer (TNBC) did not significantly worsen patients' quality of life, according to new data from the IMpassion031 trial. In the randomized p...
